REFERENCES
- Aronoff S, Rosenblatt S, Braithwaite S, Egan J W, Mathisen A L, Schneider R L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605–1611, [PUBMED], [INFOTRIEVE], [CSA]
- Baron A D. Insulin resistance and vascular function. J Diabetes Complications 2002; 16: 92–102, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Caballero A E, Arora S, Saouaf R, Lim S C, Smakowski P, Park J Y, King G L, LoGerfo F W, Horton E S, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856–1862, [PUBMED], [INFOTRIEVE], [CSA]
- Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36–52, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chinetti G, Griglio S, Antonucci M, Torra I P, Delerive P, Majd Z, Fruchart J C, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573–25580, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Diep Q N, El Mabrouk M, Cohn J S, Endemann D, Amiri F, Virdis A, Neves M F, Schiffrin E L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296–2302, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Feener E P, King G L. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350(Suppl 1)SI9–SI13, [PUBMED], [INFOTRIEVE], [CSA]
- Forst T, Pfützner A, Hasselbach Y, Lehnert H, Beyer J. Evaluation of neuropathic involvement by fibre type in patients with either insulin-dependent or non-insulin-dependent diabetes with and without neurotrophic foot ulceration. Diabetes Nutr Metab 1995; 8: 292–297, [CSA]
- Forst T, Pfutzner A, Kunt T, Pohlmann T, Schenk U, Bauersachs R, Kustner E, Beyer J. Skin microcirculation in patients with type I diabetes with and without neuropathy after neurovascular stimulation. Clin Sci 1998; 94: 255–261, [PUBMED], [INFOTRIEVE], [CSA]
- Fullert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G, Usadel K H, Konrad T. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503–5506, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ghazzi M N, Perez J E, Antonucci T K, Driscoll J H, Huang S M, Faja B W, Whitcomb R W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46: 433–439, [PUBMED], [INFOTRIEVE], [CSA]
- Hanefeld M, Brunetti P, Schernthaner G H, Matthews D R, Charbonnel B H, QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141–147, [PUBMED], [INFOTRIEVE], [CSA]
- Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects: results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000; 17: 299–307, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Inzucchi S E, Maggs D G, Spollett G R, Page S L, Rife F S, Walton V, Shulman G I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867–872, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jaap A J, Hammersley M S, Shore A C, Tooke J E. Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1994; 37: 214–216, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jaap A J, Shore A C, Tooke J E. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997; 40: 238–243, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jiang C, Ting A T, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82–86, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kubli S, Waeber B, Dalle-Ave A, Feihl F. Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol 2000; 36: 640–648, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lee B C, Shore A C, Humphreys J M, Lowe G D, Rumley A, Clark P M, Hattersley A T, Tooke J E. Skin microvascular vasodilatory capacity in offspring of two parents with Type 2 diabetes. Diabet Med 2001; 18: 541–545, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McVeigh G E, Brennan G M, Johnston G D, McDermott B J, McGrath L T, Henry W R, Andrews J W, Hayes J R. Impaired endothelium-dependent and independent vasodilatation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771–776, [PUBMED], [INFOTRIEVE], [CSA]
- Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino L J, DeFronzo R A. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710–719, [PUBMED], [INFOTRIEVE], [CSA]
- Morris S J, Shore A C, Tooke J E. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995; 38: 1337–1344, [PUBMED], [INFOTRIEVE], [CSA]
- Nitenberg A, Valensi P, Sachs R, Cosson E, Attali J R, Antony I. Prognostic value of epicardial coronary artery constriction to the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care 2004; 27: 208–215, [PUBMED], [INFOTRIEVE], [CSA]
- Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316–320, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Parkhouse N, LeQuesne P M. Quantitative objective assessment of peripheral nociceptive C-fibre function. J Neurol Neurosurg Psychiatry 1988; 51: 28–34, [PUBMED], [INFOTRIEVE], [CSA]
- Pasceri V, Wu H D, Willerson J T, Yeh E T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235–238, [PUBMED], [INFOTRIEVE], [CSA]
- Pfutzner A, Forst T, Engelbach M, Margin T, Goitom K, Lobig M, Beyer J, Kunt T. The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus. Diabet Med 2001; 18: 489–494, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484–490, [PUBMED], [INFOTRIEVE], [CSA]
- Sandeman D D, Pym C A, Green E M, Seamark C, Shore A C, Tooke J E. Microvascular vasodilatation in feet of newly diagnosed non-insulin dependent diabetic patients. BMJ 1991; 302: 1122–1123, [PUBMED], [INFOTRIEVE], [CSA]
- Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511–2515, [PUBMED], [INFOTRIEVE], [CSA]
- Shankar R R, Wu Y, Shen H Q, Zhu J S, Baron A D. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 2000; 49: 684–687, [PUBMED], [INFOTRIEVE], [CSA]
- Smits P, Kapma J A, Jacobs M C, Lutterman J, Thien T. Endothelium dependent vascular relaxation in patients with type 1 diabetes. Diabetes 1993; 42: 148–153, [PUBMED], [INFOTRIEVE], [CSA]
- St John S M, Rendell M, Dandona P, Dole J F, Murphy K, Patwardhan R, Patel J, Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058–2064, [CSA]
- Stansberry K B, Peppard H R, Babyak L M, Popp G, McNitt P M, Vinik A I. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes. Diabetes Care 1999; 9: 1549–1554, [CSA]
- Steinberg H O, Baron A D. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623–634, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Steinberg H O, Brechtel G, Johnson A, Fineberg N, Baron A D. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172–1179, [PUBMED], [INFOTRIEVE], [CSA]
- Tooke J E. Peripheral microvascular disease in diabetes. Diabetes Res Clin Pract 1996; 30(Suppl)S61–S65, [CSA]
- Tooke J E, Goh K L. Vascular function in Type 2 diabetes mellitus and pre-diabetes: the case for intrinsic endotheiopathy. Diabet Med 1999; 16: 710–715, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tur E, Yosipovitch G, Bar-On Y. Skin reactive hyperemia in diabetic patients: a study by laser Doppler flowmetry. Diabetes Care 1991; 14: 958–962, [PUBMED], [INFOTRIEVE], [CSA]
- Veves A, Akbari C M, Primavera J, Donaghue V M, Zacharoulis D, Chrzan J S, DeGirolami U, LoGerfo F W, Freeman R. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998; 47: 457–463, [PUBMED], [INFOTRIEVE], [CSA]
- Vinik A I, Erbas T, Park T S, Stansberry K B, Scanelli J A, Pittenger G L. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1468–1475, [PUBMED], [INFOTRIEVE], [CSA]
- Vinik A I, Stansberry K B, Barlow P M. Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 279–285, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Walker A B, Chattington P D, Buckingham R E, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448–1453, [PUBMED], [INFOTRIEVE], [CSA]
- Walmsley D, Wiles P G. Early loss of neurogenic inflammation in the human diabtic foot. Clin Sci 1991; 80: 605–610, [PUBMED], [INFOTRIEVE], [CSA]
- Williams S B, Cusco J A, Roddy M A, Johnstone M T, Creager M A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567–574, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, Baumstark M W, Krebs K, Wieland H, Marz W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2588–2594, [PUBMED], [INFOTRIEVE], [CSA]
- Zeng G, Nystrom F H, Ravichandran L V, Cong L N, Kirby M, Mostowski H, Quon M J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539–1545, [PUBMED], [INFOTRIEVE], [CSA]